If you’re looking for certainty in immuno-oncology, Bristol-Myers’ latest Opdivo-plus-Yervoy data won't help.

Facebook is the social media platform most pharma marketers plan to use in the next two years, followed by YouTube, LinkedIn and Twitter.

Should the FDA cut down drug-risk statements in TV ads? The not-surprising finding of a new agency study—short lists are easier to recall—suggests so.

Novartis' Entresto to treat heart failure had a tough launch at $4,600 a year, but the product is starting to turn around.

MannKind and One Drop hope to prove the inhaled insulin Afrezza works better for patients when paired with a digital management diabetes system.

Not every baseball fan wants peanuts and Cracker Jack—especially fans with severe allergies. But Kaléo has a solution.

Tesaro’s PARP contender Zejula has only been around since April, but that’s all the time it needed to snag the No. 1 position in the space.

It wasn’t long ago that Lundbeck was struggling. But thanks to some new launches, the company is poised to post its best-ever financial year.